|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
NovaDel Pharma (NVD) Reports Unaudited Financial Results for the Nine Months Ended September 30, 2012
11/15/2012 10:28:04 AM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (NVDL.PK) reported unaudited financial results for the nine months ended September 30, 2012. As previously reported, the Company continues to seek financing or a strategic partner. The Company, at the end of March 2012, deregistered its common stock and exited the Securities and Exchange Commission reporting system. The Company recorded a loss of $1,302,000 or $(0.01) per share for the nine months ended September 30, 2012 compared to a net loss of $6,425,000 or $(0.05) per share in the nine months ended September 30, 2011. During the nine months of 2012, the Company earned royalties from the license of NitroMist and Zolpimist in the amount of $345,000. The Company also received $200,000 from the sale of NitroMist rights outside the US, Canada and Mexico. Also included in revenue is the recognition of previously received payments under various license agreements.
|
|
|
|
|
|
|
|
|
|
|